TY - JOUR
T1 - Comparing Survival after Resection of Pancreatic Cancer with and without Pancreatic Cysts
T2 - Nationwide Registry-Based Study
AU - Gorris, Myrte
AU - van Huijgevoort, Nadine C. M.
AU - Farina, Arantza
AU - Brosens, Lodewijk A. A.
AU - van Santvoort, Hjalmar C.
AU - Groot Koerkamp, Bas
AU - Bruno, Marco J.
AU - Besselink, Marc G.
AU - on behalf of the Dutch Pancreatic Cancer Group
AU - van Hooft, Jeanin E.
N1 - Publisher Copyright: © 2022 by the authors.
PY - 2022/9/1
Y1 - 2022/9/1
N2 - Background: Outcome after resection of pancreatic ductal adenocarcinoma associated with pancreatic cystic neoplasms (PCN-PDAC) might differ from PDAC not associated with PCN. This nationwide, registry-based study aimed to compare the overall survival (OS) in these patients. Methods: Data from consecutive patients after pancreatic resection for PDAC between 2013 and 2018 were matched with the corresponding pathology reports. Primary outcome was OS for PCN-PDAC and PDAC including 1-year and 5-year OS. Cox regression analysis was used to correct for prognostic factors (e.g., pT-stage, pN-stage, and vascular invasion). Results: In total, 1994 patients underwent resection for PDAC including 233 (12%) with PCN-PDAC. Median estimated OS was better in patients with PCN-PDAC (34.5 months [95%CI 25.6 to 43.5]) as compared to PDAC not associated with PCN (18.2 months [95%CI 17.3 to 19.2]; hazard ratio 0.53 [95%CI 0.44–0.63]; p < 0.001). The difference in OS remained after correction for prognostic factors (adjusted hazard ratio 1.58 [95%CI 1.32−1.90]; p < 0.001). Conclusions: This nationwide registry-based study showed that 12% of resected PDAC were PCN-associated. Patients with PCN-PDAC had better OS as compared to PDAC not associated with PCN.
AB - Background: Outcome after resection of pancreatic ductal adenocarcinoma associated with pancreatic cystic neoplasms (PCN-PDAC) might differ from PDAC not associated with PCN. This nationwide, registry-based study aimed to compare the overall survival (OS) in these patients. Methods: Data from consecutive patients after pancreatic resection for PDAC between 2013 and 2018 were matched with the corresponding pathology reports. Primary outcome was OS for PCN-PDAC and PDAC including 1-year and 5-year OS. Cox regression analysis was used to correct for prognostic factors (e.g., pT-stage, pN-stage, and vascular invasion). Results: In total, 1994 patients underwent resection for PDAC including 233 (12%) with PCN-PDAC. Median estimated OS was better in patients with PCN-PDAC (34.5 months [95%CI 25.6 to 43.5]) as compared to PDAC not associated with PCN (18.2 months [95%CI 17.3 to 19.2]; hazard ratio 0.53 [95%CI 0.44–0.63]; p < 0.001). The difference in OS remained after correction for prognostic factors (adjusted hazard ratio 1.58 [95%CI 1.32−1.90]; p < 0.001). Conclusions: This nationwide registry-based study showed that 12% of resected PDAC were PCN-associated. Patients with PCN-PDAC had better OS as compared to PDAC not associated with PCN.
KW - Kaplan–Meier estimates
KW - pancreatic cyst
KW - pancreatic neoplasms
KW - surgical oncology
KW - survival analyses
UR - http://www.scopus.com/inward/record.url?scp=85137886340&partnerID=8YFLogxK
U2 - https://doi.org/10.3390/cancers14174228
DO - https://doi.org/10.3390/cancers14174228
M3 - Article
C2 - 36077765
SN - 2072-6694
VL - 14
JO - Cancers
JF - Cancers
IS - 17
M1 - 4228
ER -